We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice

Cookies settings I agree I disagree

Cookies information

Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:

Statistic

We use tools such as Google Analytics to track web traffic and check the effectiveness of our site.

Necessary

Cookies required for essential services and features such as login forms, shopping cart integration and access control. Without them, our website cannot function properly and we cannot provide any services. Deactivation is not available.

These settings will be kept for 24h

Media Articles

Understanding neuroinflammation is key to new treatments for stroke

Understanding neuroinflammation is key to new treatments for stroke
Check the link
Media Articles
Understanding neuroinflammation is key to new treatments for stroke

Our CEO Marc Dechamps took a deep-dive into the fundamental causes of hemorrhagic stroke this month, speaking at length about neuroinflammation in an interview published in the widely read European Biopharmaceutical Review (EBR).

Understanding neuroinflammation is a crucial expertise for Bioxodes, which is developing a treatment for intracerebral hemorrhagic stroke, a condition which causes 40% of all stroke-related deaths, but for which no treatment is currently available.

Neuroinflammation is a natural reaction of the body’s immune system to injury in the brain. But too much of it during the acute phase of a hemorrhagic stroke can cause worse neurological outcomes, Dechamps says in the article.

With its drug candidate BIOX-101, Bioxodes aims to reduce these harmful secondary effects of ICH – but without causing further bleeding. BIOX-101 does this by targeting the release of extracellular traps (NETs) by neutrophils, a type of white blood cell, as well as the coagulation factors FXIIa and FXIa.

Neutrophils act as early responders to cerebral injury, but can also contribute to further damage. Preventing the formation of secondary microthrombi by inhibiting FXIIa and FXIa offers an additional way to mitigate cerebral injuries in ICH.

You can read the full article here (highly recommended!): 👉 https://lnkd.in/e6xcxMYA